display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - EGFR mutant
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
durvalumab plus osimertinib CAURAL ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons